Diabetic Neuropathy Recommendations

2016 ADA Guideline Recommendations

Types of Diabetes Mellitus

Main Diabetes Page

Diabetes type I

Diabetes type II

Gestational Diabetes Mellitus

2016 ADA Standard of Medical Care Guideline Recommendations

Strategies for Improving Care

Classification and Diagnosis of Diabetes

Foundations of Care and Comprehensive Medical Evaluation

Diabetes Self-Management, Education, and Support
Nutritional Therapy

Prevention or Delay of Type II Diabetes

Glycemic Targets

Obesity Management for Treatment of Type II Diabetes

Approaches to Glycemic Treatment

Cardiovascular Disease and Risk Management

Hypertension and Blood Pressure Control
Lipid Management
Antiplatelet Agents
Coronary Heart Disease

Microvascular Complications and Foot Care

Diabetic Kidney Disease
Diabetic Retinopathy
Diabetic Neuropathy
Diabetic Footcare

Older Adults with Diabetes

Children and Adolescents with Diabetes

Management of Cardiovascular Risk Factors in Children and Adolescents with Diabetes
Microvascular Complications in Children and Adolescents with Diabetes

Management of Diabetes in Pregnancy

Diabetes Care in the Hospital Setting

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:  Shivani Chaparala M.B.B.S [2]; Tarek Nafee, M.D. [3]

## 2016 ADA Standards of Medical Care in Diabetes Guidelines[1]

[edit | edit source]

#### Screening

[edit | edit source]

"1. All patients should be assessed for diabetic peripheral neuropathy starting at diagnosis of type 2 di- abetes and 5 years after the diag- nosis of type 1 diabetes and at least annually thereafter. (Level of Evidence: B)"

"2. Assessment should include a careful history and 10-g monofilament testing and at least one of the following tests: pinprick, temperature, or vibration sensation. (Level of Evidence: B)"
"3.Symptoms and signs of autonomic neuropathy should be assessed in patients with microvascular and neuropathic complications. (Level of Evidence: E)"

#### Treatment

[edit | edit source]

"1. Optimize glucose control to pre- vent or delay the development of neuropathy in patients with type 1 diabetes A and to slow the pro- gression of neuropathy in patients with type 2 diabetes. (Level of Evidence: B)"

"2. Assess and treat patients to reduce pain related to diabetic peripheral neuropathy B and symptoms of au- tonomic neuropathy and to im- prove quality of life. (Level of Evidence: E)"

## References

[edit | edit source]

1. ↑ "care.diabetesjournals.org" (PDF).

Template:WHTemplate:WS